MX2022006307A - Agonistas del receptor tipo toll 7 (tlr7). - Google Patents

Agonistas del receptor tipo toll 7 (tlr7).

Info

Publication number
MX2022006307A
MX2022006307A MX2022006307A MX2022006307A MX2022006307A MX 2022006307 A MX2022006307 A MX 2022006307A MX 2022006307 A MX2022006307 A MX 2022006307A MX 2022006307 A MX2022006307 A MX 2022006307A MX 2022006307 A MX2022006307 A MX 2022006307A
Authority
MX
Mexico
Prior art keywords
tlr7 agonists
tlr7
agonists
cancer
diseases
Prior art date
Application number
MX2022006307A
Other languages
English (en)
Inventor
Stephen E Webber
James Richard Appleman
Original Assignee
Primmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primmune Therapeutics Inc filed Critical Primmune Therapeutics Inc
Publication of MX2022006307A publication Critical patent/MX2022006307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a agonistas de TLR7 según la fórmula I y su uso en el tratamiento de enfermedades como el cáncer y las enfermedades infecciosas (ver fórmula I).
MX2022006307A 2019-11-26 2020-11-25 Agonistas del receptor tipo toll 7 (tlr7). MX2022006307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940622P 2019-11-26 2019-11-26
PCT/US2020/062344 WO2021108649A1 (en) 2019-11-26 2020-11-25 Tlr7 agonists

Publications (1)

Publication Number Publication Date
MX2022006307A true MX2022006307A (es) 2022-08-22

Family

ID=75974715

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006307A MX2022006307A (es) 2019-11-26 2020-11-25 Agonistas del receptor tipo toll 7 (tlr7).

Country Status (17)

Country Link
US (2) US11692005B2 (es)
EP (1) EP4065155A4 (es)
JP (1) JP2023503996A (es)
KR (1) KR20220150879A (es)
CN (1) CN115427063A (es)
AU (1) AU2020391487A1 (es)
BR (1) BR112022010165A2 (es)
CA (1) CA3163093A1 (es)
CL (1) CL2022001377A1 (es)
CO (1) CO2022008835A2 (es)
CR (1) CR20220282A (es)
EC (1) ECSP22049906A (es)
IL (1) IL293293A (es)
MX (1) MX2022006307A (es)
PE (1) PE20221324A1 (es)
TW (1) TW202134240A (es)
WO (1) WO2021108649A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5136030A (en) 1988-05-05 1992-08-04 Scripps Clinic And Research Foundation Immunostimulating guanine derivatives, compositions and methods
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
AU5845594A (en) 1992-11-13 1994-06-08 Scripps Research Institute, The Cancerous b cell treatment using substituted nucleoside derivatives
ATE271063T1 (de) 1996-10-16 2004-07-15 Icn Pharmaceuticals Purin-l-nukleoside, deren analoga und verwendungen
TR200601784T2 (tr) 1999-11-12 2007-01-22 Pharmasset Ltd. 2'-deoksi-L-nükleositlerin sentezi
NZ521210A (en) 2000-02-18 2004-11-26 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
CA2537450C (en) 2003-09-05 2012-04-17 Anadys Pharmaceuticals, Inc. Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
TWI407956B (zh) 2004-12-17 2013-09-11 Anadys Pharmaceuticals Inc ３，５-二取代和３，５，７-三取代-３Ｈ-唑并及３Ｈ-噻唑并〔４，５-ｄ〕嘧啶-２-酮化合物及其前藥
AU2008286735A1 (en) 2007-08-15 2009-02-19 Idera Pharmaceuticals, Inc. Toll like receptor modulators
CA2732437C (en) 2008-08-01 2017-11-21 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
WO2010111290A1 (en) 2009-03-23 2010-09-30 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
CN104661683A (zh) 2011-11-09 2015-05-27 埃森德生物制药有限公司 免疫调节缀合物
KR102462743B1 (ko) 2014-07-09 2022-11-02 버디 바이오파마슈티칼즈, 인크. 종양 치료용 항-pd-l1 조합
PL3230298T3 (pl) 2014-12-08 2021-06-14 F.Hoffmann-La Roche Ag 3-podstawione związki 5-amino-6h-tiazolo[4,5-d]pirymidyno-2,7-dionowe do leczenia i profilaktyki zakażenia wirusowego
SG10201912847QA (en) 2015-03-16 2020-02-27 Hoffmann La Roche Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
NZ755222A (en) 2016-12-20 2022-07-01 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer
KR20210035095A (ko) 2018-05-25 2021-03-31 프리뮨 테라퓨틱스, 인크. Tlr7 효능제

Also Published As

Publication number Publication date
IL293293A (en) 2022-07-01
ECSP22049906A (es) 2022-07-29
BR112022010165A2 (pt) 2022-08-09
US20210155652A1 (en) 2021-05-27
JP2023503996A (ja) 2023-02-01
KR20220150879A (ko) 2022-11-11
TW202134240A (zh) 2021-09-16
US11692005B2 (en) 2023-07-04
CO2022008835A2 (es) 2022-07-19
EP4065155A4 (en) 2023-11-29
CN115427063A (zh) 2022-12-02
CA3163093A1 (en) 2021-06-03
CR20220282A (es) 2022-11-28
EP4065155A1 (en) 2022-10-05
PE20221324A1 (es) 2022-09-09
WO2021108649A1 (en) 2021-06-03
CL2022001377A1 (es) 2023-04-10
US20240116974A1 (en) 2024-04-11
AU2020391487A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
MX2019012233A (es) Anticuerpos anti-sirpa.
PH12020551994A1 (en) Tlr7 agonists
MX2019001920A (es) Arn la terapia contra el cancer.
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
MY183036A (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12020500396A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2019012676A (es) Derivados de 2-aminoquinolina.
MX2022007522A (es) Anticuerpos anti-cd27.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2015010125A (es) Derivados de piridazinona-amidas.
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
NZ764310A (en) Antibacterial compounds
MX2020011826A (es) Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
WO2019040105A3 (en) COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES
MX2022006307A (es) Agonistas del receptor tipo toll 7 (tlr7).
MX2022003398A (es) Composicion micelar inmunoestimulante.
MX2019004375A (es) Inhibidores de bromodominios.
EA201990834A1 (ru) Пиримидиновые пролекарства для лечения вирусных инфекций и других заболеваний
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases